In the rapidly evolving landscape of therapeutic protein development, the integration of Artificial Intelligence (AI) has shifted the paradigm from “discovery via screening” to “discovery via design.” However, even the most sophisticatedRead More…
Agonist vs. Antagonist vs. Allosteric Modulator: A Design-Centric Guide for Protein Therapeutics
In the landscape of modern drug discovery, the era of simply finding a molecule that “binds” to a target is over. The contemporary challenge lies in functional precision—dictating exactly how a therapeuticRead More…
Reinventing Drug Discovery with AI De Novo Design
De novo drug design has moved from a niche computational exercise to a central pillar of AI-driven drug discovery. With rising R&D costs, multi-year timelines, and high attrition rates, the ability toRead More…
AI in Natural Product Drug Discovery: Now & Next
As operators of Creative Biolabs’ AI Station, we’ve watched artificial intelligence move natural-product (NP) drug discovery from scattered experiments to data-driven pipelines. A recent perspective captures this shift with unusual clarity: AIRead More…
How AI and Computational Biology are Revolutionizing mRNA Vaccine Design
The landscape of cancer treatment is undergoing a radical transformation, driven by the emergence of messenger RNA (mRNA) vaccines. These versatile and scalable platforms are not just a new tool; they representRead More…
AI-Powered De Novo Antibody Design Targeting SARS-CoV-2
The design of therapeutic antibodies has long been a cornerstone of modern biopharmaceutical innovation. Yet traditional discovery pipelines—reliant on animal immunization, patient-derived antibodies, and wet-lab optimization—are inherently slow, costly, and difficult toRead More…
AI-Powered Antibody Discovery: Accelerating Innovation While Minimizing Risk
In the evolving landscape of biologics, monoclonal antibodies (mAbs) have emerged as one of the most powerful therapeutic modalities, offering high specificity, prolonged half-life, and unparalleled versatility in disease targeting. Yet, despiteRead More…
AI-Driven Strategies for Fast and Precise Antibody–Antigen Engineering
Artificial intelligence (AI) is rapidly transforming the landscape of therapeutic antibody discovery and engineering. As the biopharmaceutical industry continues to demand faster, more precise, and cost-effective development pipelines, AI-driven solutions have emergedRead More…
Harnessing AI to Revolutionize Antibody Design in Oncology
Antibody-based therapeutics have emerged as one of the most successful classes of biologics for cancer treatment. Yet, the development of these complex biomolecules remains a formidable task, requiring the integration of structuralRead More…
Transforming Antibody Development: The Power of AI-Based Engineering
Introduction: The New Era of Antibody Engineering The field of antibody engineering has driven biomedical innovation for many years by supplying crucial resources for therapeutic development and research diagnostics. Hybridoma technology andRead More…
